(NASDAQ:ARVN), who have seen the share price tank a massive 86% over a three year period. That might cause some serious doubts about the merits of the initial decision to buy the stock, to put it ...

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...

Because Arvinas made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually ...

Arvinas believes the differentiated pharmacology of ARV-471, including its iterative degradation activity, has the potential to translate into meaningful clinical benefit for patients.

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Arvinas (ARVN) to $10 from $19 and keeps a Neutral rating on the shares after its VERITAC-2 trial failed to meet the primary ...

Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the previous year, the business earned ($2.53) earnings per share.

For example, Arvinas, Inc. (NASDAQ:ARVN) shareholders have seen the share price rise 80% over three years, well in excess of the market return (41%, not including dividends).

A downtrend has been apparent in Arvinas, Inc. (ARVN) lately. While the stock has lost 14.4% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last ...

This represents a potential first for preclinical evidence of anti-tumor activity by an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model. Furthermore, ARV-393 monotherapy ...

Arvinas on Wednesday said Houston, who has been president and chief executive of the New Haven, Conn., company since September 2017, will retire from those positions upon the appointment of a ...

The stock price of Arvinas (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, reached an all-time high of $108 in July of this year ...

Shares of Arvinas (ARVN -2.02%) rallied nearly 10% during Thursday's trading session, in response to the announcement of a new collaboration with drug giant Pfizer (PFE -0.04%).